PT - JOURNAL ARTICLE AU - Matthew J. O’Neill AU - Luca Sala AU - Isabelle Denjoy AU - Yuko Wada AU - Krystian Kozek AU - Lia Crotti AU - Federica Dagradi AU - Maria-Christina Kotta AU - Carla Spazzolini AU - Antoine Leenhardt AU - Joe-Elie Salem AU - Asami Kashiwa AU - Seiko Ohno AU - Ran Tao AU - Dan M. Roden AU - Minoru Horie AU - Fabrice Extramiana AU - Peter J. Schwartz AU - Brett M. Kroncke TI - Continuous Bayesian Variant Interpretation Accounts for Incomplete Penetrance among Mendelian Cardiac Channelopathies AID - 10.1101/2022.07.07.22277385 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.07.22277385 4099 - http://medrxiv.org/content/early/2022/07/09/2022.07.07.22277385.short 4100 - http://medrxiv.org/content/early/2022/07/09/2022.07.07.22277385.full AB - Background The congenital Long QT Syndrome (LQTS) and Brugada Syndrome (BrS) are Mendelian autosomal dominant diseases which frequently precipitate fatal cardiac arrhythmias. Incomplete penetrance is a barrier to clinical management of heterozygotes harboring variants in the major implicated disease genes KCNQ1, KCNH2, and SCN5A. We apply and evaluate a Bayesian penetrance estimation strategy that accounts for this phenomenon and evaluate penetrance distributions and rationalize their structural underpinnings across four genotype-phenotype pairs.Methods We generated Bayesian penetrance estimation models for KCNQ1-LQT1 and SCN5A-LQT3 using variant-specific features and clinical data from the literature, international arrhythmia genetic centers, and population controls. We analyzed the distribution of posterior penetrance estimates across four-genotype phenotype relationships and compared continuous estimates to ClinVar annotations. Posterior estimates were mapped onto protein structure.Results Bayesian models of KCNQ1-LQT1 and SCN5A-LQT3 are well-calibrated to clinical observations. Variant-informed penetrance estimates of KCNQ1-LQT1 and SCN5A-LQT3 are empirically equivalent to 10 and 5 heterozygote clinical phenotypes, respectively. Posterior penetrance estimates were bimodal for KCNQ1-LQT1 and KCNH2-LQT2, with a higher fraction of missense variants with high penetrance among KCNQ1 variants. SCN5A-LQT3 and SCN5A-BrS had comparatively more variants with predicted low penetrance. There was a wide distribution of variant penetrance estimates among similar categories of ClinVar annotations. Structural mapping revealed heterogeneity among ‘hot spot’ regions and featured high penetrance estimates for KCNQ1 variants in contact with calmodulin and the S6 domain.Conclusions Bayesian penetrance estimates provide a continuous framework for variant interpretation, provide higher resolution within ‘hot spot’ domains, and facilitate prospective clinical management of variant heterozygotes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by American Heart Association 907581 (MJO), a Marie Skłodowska-Curie Individual Fellowship (H2020-MSCA-IF-2017; Grant Agreement No. 795209, LS), a Fondazione CARIPLO, Biomedical Research Conducted by Young Researchers (Grant No. 2019-1691, LS), NIH R01HL160863 (BMR), American Heart Association 848898 (BMR), Leducq Foundation for Cardiovascular Research grant 18CVD05 (LC, JES, PJS, BMR), and partially supported by the Italian Ministry of Health (LS, LC, FD, MCK, CS, PJS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board (#191563) of Vanderbilt University Medical Center granted a waiver for this work based on 45 CFR 46.104 (d) category (4) for Exempt Review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://variantbrowser.org/